Targeting two brain tumor-associated proteins-;rather than one-;with CAR T cell therapy shows promise as a strategy for reducing solid tumor growth in patients with recurrent glioblastoma (GBM), an aggressive form of brain cancer, according to early results from the first six patients treated in an ongoing Phase I clinical trial led by researchers from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine’s Abramson Cancer Center.
Regenxbio shares first data showing Duchenne gene therapy improves muscle function
Regenxbio said its gene therapy improved muscle function in a handful of boys with Duchenne muscular dystrophy across two doses. The gene therapy company said
November 19, 2024